| Literature DB >> 23543285 |
Isabelle Franceschini1, Elodie Desroziers.
Abstract
The prominent role of the G protein coupled receptor GPR54 and its peptide ligand kisspeptin in the progression of puberty has been extensively documented in many mammalian species including humans. Kisspeptins are very potent gonadotropin-releasing hormone secretagogues produced by two main populations of neurons located in two ventral forebrain regions, the preoptic area and the arcuate nucleus. Within the last 2 years a substantial amount of data has accumulated concerning the development of these neuronal populations and their timely regulation by central and peripheral factors during fetal, neonatal, and peripubertal stages of development. This review focuses on the development of the kisspeptin-GPR54 system in the brain of female mice, rats, sheep, monkeys, and humans. We will also discuss the notion that this system represents a major target through which signals from the environment early in life can reprogram reproductive function.Entities:
Keywords: GPR54; differentiation; environment; kisspeptin; neuron; ontogenesis; regulation; reproduction
Year: 2013 PMID: 23543285 PMCID: PMC3610010 DOI: 10.3389/fendo.2013.00022
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Neuroanatomy of the kisspeptin–GPR54 system. Simplified scheme of a midsagittal section through the ventral forebrain, representing the neuroanatomy of the kisspeptin–GPR54 system. Two anatomically and phenotypically distinct populations of kisspeptin neurons (green) control GnRH (red) secretion: kisspeptin neurons in the POA drive GnRH surges and kisspeptin cells in the ARC modulate the tonic pulsatile release of GnRH. Both populations of kisspeptin neurons interact with GnRH neurons in part directly. A, anterior; P, posterior; D, dorsal; V, ventral; POA, preoptic area; ARC, arcuate nucleus; OC, optic chiasm, VMH, ventromedial hypothalamus; MB, mammillary bodies; APit, anterior pituitary; PPit, posterior pituitary.
Summary of studies showing a role of kisspeptin–GPR54 system in the development of female reproductive function.
| Approaches | Species | Reference | Manipulation | Period of manipulation | Time of analysis | Physiological impact | Hypothalamic analysis |
|---|---|---|---|---|---|---|---|
| Genetic | Human | Seminara et al. ( | GPR54 mutations (loss of function) | Congenital | Adult | IHH | |
| Teles et al. ( | GPR54 mutations (gain of function) | Child | ICPP | ||||
| Silveira et al. ( | Kiss1 mutations | Congenital | Child | IHH and ICPP | |||
| Topaloglu et al. ( | Child and Adult | IHH | |||||
| Mouse | Seminara et al. ( | GPR54-KO | Congenital | Peripubertal to adult | HH, puberty delayed, no estrus cycle | No change in GnRH content (RIA) | |
| Funes et al. ( | Peripubertal to adult | HH, infertility | |||||
| Lapatto et al. ( | Peripubertal to adult | HH, puberty delayed, no estrus cycle | |||||
| Dungan et al. ( | Peripubertal to adult | HH, low circulating LH even after ovariectomy | No change in GnRH cell numbers | ||||
| Clarkson et al. ( | Peripubertal to adult | Compromised ability to mount LH surges | |||||
| Lapatto et al. ( | Kiss1-KO | Congenital | Peripubertal to adult | HH, puberty delayed, no estrus cycle | |||
| d’Anglemont de Tassigny et al. ( | Peripubertal to adult | HH, puberty delayed, low circulating LH levels | No change in GnRH content (RIA), GnRH cell numbers and median eminence fiber density | ||||
| Mayer and Boehm ( | Kiss1 cell ablation Kiss1-DTA | Congenital | Prepubertal (P20) and adult | HH, estrus cycle present but less regular than control | Decrease in Kiss1 mRNA in ARC and kisspeptin-immunoreactive cell numbers in POA | ||
| Kiss1 conditional cell ablation | Prepubertal (P20) | Pubertal (P40) and adult | No estrus cycle: persistent diestrous, infertility | ||||
| Pharmacological | Rat | Matsui et al. ( | Kp s.c. injection (acute) | Prepubertal (P25) | Prepubertal (P25) | Increase in circulating LH | Effect abolished by GnRH receptor antagonist |
| Navarro et al. ( | Kp i.c.v. injection (acute) | Prepubertal (P25) | Prepubertal (P25) | Increase in circulating LH, decrease in circulating prolactin | |||
| Navarro et al. ( | Kp i.c.v. injections (chronic) | Prepubertal (P26–P31) | Prepubertal (P26–P31) | Puberty advanced, increase of uterus weight, increase in circulating LH and E2 | LH-releasing effect abolished by GnRH receptor antagonist | ||
| Castellano et al. ( | Kp i.p. injection (acute) | Neonatal (P5), Prepubertal (P15 and P25) | Neonatal (P5), Prepubertal (P15 and P25) | Increase in circulating LH but significant only at P15 | |||
| Pineda et al. ( | GPR54-antagonist i.c.v. infusion | Prepubertal (from P30 to P36) | Prepubertal (P36) | Puberty delayed | |||
| Sheep | Redmond et al. ( | Kp i.v. injection | Prepubertal (28 W) | Prepubertal (28 W) | Increase in LH pulsatility (frequency and amplitude) and circulating E2 | ||
| Monkey | Guerriero et al. ( | Kp i.c.v. injection | Prepubertal (52–81 W) and pubertal (112–175 W) | Prepubertal (52–81 W) and pubertal (112–175 W) | Increase in GnRH pulsatile release GNRH-response to kp increases at puberty | ||
| GPR54-antagonist i.c.v. injection | Prepubertal (52–81 W) and pubertal (112–175 W) | Prepubertal (52–81 W) and pubertal (112–175 W) | Decrease in GnRH pulsatile release only at prepubertal stage | ||||
| Roseweir et al. ( | GPR54-antagonist i.c.v. injection | Pubertal (132 W) | Pubertal (132 W) | Decrease in GnRH pulsatile release and basal GnRH (microdialysis) | |||
IHH, idiopathic hypogonadotropic hypogonadism; ICPP, idiopathic central precocious puberty; HH, hypogonadotropic hypogonadism; s.c., sub cutaneous; i.v., intravenous; i.p., intraperitoneal; i.c.v., intracerebroventricular; RIA, radioimmunoassay; POA, preoptic area; ARC, arcuate nucleus; ME, median eminence; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; E2, estradiol; P, postnatal day; W, weeks.
Figure 2Kisspeptin-immunoreactive cells and fibers in the ARC and median eminence at embryonic day E18.5 in rats. Schematic mid sagittal view of embryonic head at E18.5 (A) (adapted from Paxinos and Ashwell, 2008) with a higher resolution of the embryonic hypothalamus (B) [corresponding to the box in (A)] depicting the area were kisspeptin-immunoreactive cells were detected (green dots). Numerous kisspeptin-immunoreactive cells were detected in the ARC at embryonic day (E) 18.5 as shown on this immunoperoxidase-labeled brain section with anti-kisspeptin AC067 (C) [corresponding to the box in (B)]. In the median eminence, close appositions (white arrows) between kisspeptin fibers (green) and GnRH fibers (red) were detected as shown in this confocal optical section of a slice double immunofluorescence-labeled for kisspeptin (sheep anti-5-18 kisspeptin 52 # AC067, Desroziers et al., 2012a) and GnRH (rabbit anti-2-10 GnRH # 19900, Caldani et al., 1988) and counterstained with Hoechst nuclear marker (D). A, anterior; P, posterior; D, dorsal; V, ventral; DB, diagonal band of Broca; aF, anterior fornix; AC, anterior commissure; PaP, paraventricular nucleus; 3V, third ventricle; OC, optic chiasma; POA, preoptic area; SO, supraoptic nucleus; ME, median eminence; VMH, ventro-medial hypothalamus; MB, mammillary bodies; Pit, pituitary; Apit, anterior pituitary; Ppit, posterior pituitary; BSph, sphenoid bones; MRe, mammillary recess. Scale bars: 100 μm (C) and 20 μm (D).
Figure 3Parallel developmental changes in . Hypothetical scheme highlighting the parallel that can be made between Kiss1 expression in the POA and ARC and the profile of GnRH/LH release across different time windows of rat development (separated from each other by grey bars on the scheme because analyzed in separate studies). POA, preoptic area; ARC, arcuate nucleus; Kp, kisspeptin; LH, luteinizing hormone.
Summary of studies showing an effect of sex steroids on the kisspeptin–GPR54 system throughout female development.
| Approaches | Species | Reference | Treatment | Period of treatment | Time of analysis | Hypothalamic impact | Physiological impact | ||
|---|---|---|---|---|---|---|---|---|---|
| Transgenetical reduction in sex steroid signalization | Mouse | González-Martínez et al. ( | Genetic deletion of alpha-fetoprotein (AFP-KO mice) | Late embryonic and neonatal period | Adult | Decrease in kp-ir cell numbers in the POA | Infertility | ||
| Gill et al. ( | Mutation of GnRH receptor, resulting in reduced sex steroid signaling (Hpg mice) | Congenital | Peripubertal (P10, P30, P45) and adult | Decrease in Kiss1 mRNA and kp-ir cell numbers in the POA, increase of Kiss1 mRNA in the ARC | Absence of vaginal opening, infertility | ||||
| Mayer et al. ( | Targeted genetic deletion of estrogen receptor alpha in kisspeptin cells | Congenital | Peripubertal (P15, P25, P35) and adult | Decrease in kp-ir cell numbers in the POA, increase in Kiss1 mRNA in the ARC | Advanced vaginal opening | ||||
| Clarkson et al. ( | Genetic deletion of aromatase (ARKO: mice) | Congenital | Adult | Ovariectomy decreases Kiss1 mRNA and kp-ir cell numbers in the POA | Infertility | ||||
| Gonadectomy ± sex steroid replacement | Mouse | Kauffman et al. ( | Ovariectomy | Prepubertal (PI4 and PI8) and adult | Prepubertal (P18) and adult | Decrease in Kiss1 cell numbers in the POA, increase in Kiss1 cell numbers in the ARC | Increase in circulating LH | ||
| Clarkson et al. ( | Ovariectomy ± E2 | Prepubertal (P15–P30 or P22–P30) | Prepubertal (P30) | Ovariectomy decreases kp-ir cell numbers in the POA. Effect reversed by E2 treatment | Increase in circulating LH. Circulating LH restored by E2 | ||||
| Rat | Takase et al. ( | Ovariectomy ± E2 | Prepubertal (P15–P21, P20–P26) | Peripubertal (P21, P26, P31, P36–41) | Ovariectomy suppresses the peripubertal increase in Kiss1 mRNA in the POA and ARC. Effect reversed by E2 treatment | Ovariectomy suppresses the peripubertal increase in circulating LH. Effect reversed by E2 treatment | |||
| Takumi et al. ( | Ovariectomy | Prepubertal (P14–P18) | Prepubertal (P18) | Decrease in Kiss1 cell numbers in the POA and ARC | |||||
| Sheep | Nestor et al. ( | Ovariectomy | Pre- (20–24 W) and post-pubertal (>36 W) | Pre- (20–24 W) and post-pubertal (>36 W) | Increase in kp-ir cell numbers in the ARC, specifically at prepubertal stage | Increase in LH pulse frequency in prepubertal stage | |||
| Monkey | Guerriero et al. ( | Ovariectomy ± E2 | Prepubertal (52–81 W) and pubertal (112–175 W) | Prepubertal (52–81 W) and pubertal (112–175 W) | Ovariectomy increases kp release specifically at pubertal stage. | ||||
| Pharmacological | Rat | Dickerson et al. ( | EB injection | Embryonic (E16–E18) | Neonatal (P1) and adult | Decrease in kp-ir fiber density in the POA (adult) | Advanced vaginal opening, decrease in circulating LH | ||
| Gore et al. ( | EB injection | Embryonic and neonatal (E19–P7) | Adult | Decrease in Kiss1 mRNA in the POA | Decrease in circulating E2, irregular estrus cycle | ||||
| Cao et al. ( | EB injection | Neonatal (P0–P2) | Neonatal (P4) and infantile (P10) | Decrease in Kiss1 mRNA from P4 in the ARC and from P10 in the POA | |||||
| Navarro et al. ( | EB injection | Neonatal (P1) | Peripubertal (P30) and adult | Decrease in hypothalamic Kiss1 mRNA | Decrease in circulating LH | ||||
| Losa et al. ( | EB or E2 injection | Neonatal (P0–P3) | Peripubertal (from P17 to P33) | Decrease in Kiss1 mRNA and kp-ir in the POA and ARC | Advanced vaginal opening | ||||
| Kauffman et al. ( | TP injection | Neonatal (P1) | Adult | Decrease in Kiss1 cell numbers in the POA but not in the ARC | Decrease in circulating LH | ||||
| Bateman and Patisaul ( | EB injection | Neonatal (P0–P3) | Adult | Decrease in kp-ir in the POA and ARC | Irregular estrus cycles, decrease in circulating LH | ||||
| Sheep | Cheng et al. ( | TP injection | End of gestation | Adult | No change in kp-ir cell numbers in the POA and ARC | Increase in circulating LH and LH pulse frequency |
POA, preoptic area; ARC, arcuate nucleus; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; kp-ir, kisspeptin-immunoreactive; EB, estradiol benzoate; TP, testosterone propionate; E2, estradiol; E, embryonic day; P, postnatal day; W, weeks.
Figure 4Neural, hormonal, and environmental factors regulating the kisspeptin–GPR54 system. Scheme summarizing the different factors that have been shown to regulate the kisspeptin–GPR54 system only during adulthood (squared by dashed lines) or also during development (squared by full lines and colored). Hormonal factors are codified by an arrow and central factors by a triangle. Molecular factors have been included whose receptors have been found on some kisspeptin neurons, factors found within fibers in close apposition to kisspeptin neurons, factors eliciting c-fos expression, or an electrophysiological response within kisspeptin neurons or changing Kiss1 or GPR54 mRNA levels, kisspeptin or GPR54 immunoreactivities, or the number of Kiss1/kisspeptin expressing cells when exogenously administered. Of note this synthetic scheme combines data from mice, rats, sheep, and monkeys and therefore occults potential species differences that may exist in these regulations. It is hypothesized that the developmental pattern of GnRH release (red graph below the tap) is shaped by interactions of these different neural and hormonal factors with an intrinsic differentiation program of the system (central clock). The developing kisspeptin–GPR54 system is particularly vulnerable to some environmental factors like endocrine disruptors, diet, and stress which can alter GnRH secretion and reproductive function on the long-term. POA, preoptic area; ARC, arcuate nucleus; E2, estradiol; T, testosterone; P4, progesterone; ER, estrogen receptor; AR, androgen receptor; PR, progestin receptor; IGF, insulin-like growth factor; IGF-R, insulin-like growth factor receptor; FGF, fibroblast growth factor; FGF-R, fibroblast growth factor receptor; GABA-R, GABA receptor; RFRP3, RF-amides related peptide-3; RFRP3-R, RFRP3 receptor; LepR, leptin receptor; Prl-R, Prolactin receptor; NKB, neurokinin B; NK3R, NKB receptor; Glut-R, glutamate receptor; VP, vasopressin; VP-R, vasopressin receptor; MCH, melanocortin; MCH-R, MCH receptor; Dyn, dynorphin; KOR, kappa-opioid receptor (Dyn-receptor); GR, Glucocorticoid receptor; CRH, corticotrophin-releasing hormone; CRH R, corticotrophin-releasing hormone receptor; D2-R, dopamine-receptor. The illustrations in the arrows were obtained from Clipart Microsoft Word®.